Search results for " GAS"

showing 10 items of 4643 documents

The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update

2017

Gluten-related disorders have recently been reclassified with an emerging scientific literature supporting the concept of non-celiac gluten sensitivity (NCGS). New research has specifically addressed prevalence, immune mechanisms, the recognition of non-immunoglobulin E (non-IgE) wheat allergy and overlap of NCGS with irritable bowel syndrome (IBS)-type symptoms. This review article will provide clinicians with an update that directly impacts on the management of a subgroup of their IBS patients whose symptoms are triggered by wheat ingestion.

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaGlutensamylase-trypsin inhibitors (ATIs)Gluten sensitivitylcsh:TX341-641Non-Celiac Gluten SensitivityReviewWheat HypersensitivityGastroenterologyIrritable Bowel Syndrome03 medical and health sciencesDiet Gluten-Free0302 clinical medicineMalabsorption Syndromesgluten-free dietMedizinische FakultätInternal medicineMedicineHumansddc:610Irritable bowel syndromeImmune mechanismsRandomized Controlled Trials as Topicgluten-related disorder030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industrygluten sensitivitynutritional and metabolic diseasesGluten-related disordersWheat-Sensitive Irritable Bowel Syndromemedicine.diseaseMalabsorption Syndromedigestive system diseasesNon-Celiac Gluten Sensitivity; Wheat-Sensitive Irritable Bowel SyndromeReview articlewheat allergy030211 gastroenterology & hepatologybusinessNon-celiac gluten sensitivitygluten-related disorderslcsh:Nutrition. Foods and food supplyWheat allergyGlutenceliac diseaseFood ScienceHuman
researchProduct

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nona…

2018

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver damage and has a strong genetic component. The rs4841132 G>A variant, modulating the expression of protein phosphatase 1 regulatory subunit 3B (PPP1R3B), which is involved in glycogen synthesis, has been reported to reduce the risk of NAFLD but at the same time may favor liver disease by facilitating glycogen accumulation. The aim of this study was to assess the impact of rs4841132 on development of histologic steatosis and fibrosis in 1,388 European individuals in a liver biopsy cohort, on NAFLD hepatocellular carcinoma in a cross-sectional Italian cohort (n = 132 cases), and on liver disease at the population level in the …

0301 basic medicinemedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAPopulation03 medical and health sciencesLiver disease0302 clinical medicineLipid oxidationFibrosisInternal medicineNonalcoholic fatty liver diseasemedicineeducationNASH NAFLDeducation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryOriginal ArticlesHepatologymedicine.diseasen/a030104 developmental biologyEndocrinologyLiver biopsy030211 gastroenterology & hepatologyOriginal ArticleSteatosisbusiness
researchProduct

P747 Predictors of thiopurine treatment failure in ulcerative colitis

2018

0301 basic medicinemedicine.medical_specialtyThiopurine methyltransferasebiologybusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisGastroenterologyTreatment failure03 medical and health sciences030104 developmental biology0302 clinical medicineInternal medicinebiology.proteinmedicine030211 gastroenterology & hepatologybusinessJournal of Crohn's and Colitis
researchProduct

Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia

2019

Background & Aims: Non-alcoholic fatty liver disease and alcohol-related liver disease pose an important challenge to current clinical healthcare pathways because of the large number of at-risk patients. Therefore, we aimed to explore the cost-effectiveness of transient elastography (TE) as a screening method to detect liver fibrosis in a primary care pathway. Methods: Cost-effectiveness analysis was performed using real-life individual patient data from 6 independent prospective cohorts (5 from Europe and 1 from Asia). A diagnostic algorithm with conditional inference trees was developed to explore the relationships between liver stiffness, socio-demographics, comorbidities, and hepati…

0301 basic medicinemedicine.medical_specialtyTransient elastographyPopulationLiver fibrosisDisease03 medical and health sciencesLiver disease0302 clinical medicineFibrosisInternal medicinemedicineeducationeducation.field_of_studyAlcohol-related liver diseaseHepatologybusiness.industryFatty liverCost-effectiveness analysismedicine.disease3. Good health030104 developmental biologyStratified screening030211 gastroenterology & hepatologyTransient elastographybusinessHepatic fibrosisNon-alcoholic fatty liver disease
researchProduct

Epidemiology ofHelicobacter pyloriinfection

2018

This review provides the most recent data concerning the epidemiology of Helicobacter pylori infection. Overall, the trend of declining prevalence of H. pylori infection is continuing, with major evidence available from studies in Europe. However, in some parts of the world, for example, in some countries in the Middle East, the prevalence has remained relatively stable. A number of systematic reviews and meta-analyses have been published during the past year indicating the lowest prevalence rates of the infection in Oceania (24.4%), the highest in Africa (79.1%), and the global annual recurrence rate of H. pylori (4.3%). The recurrence rates were found to be directly related to the human d…

0301 basic medicinemedicine.medical_specialtybusiness.industryGastroenterologyGeneral MedicineHelicobacter InfectionsEurope03 medical and health sciences030104 developmental biology0302 clinical medicineInfectious DiseasesInternal medicineNorth AmericaEpidemiologyPrevalencemedicineHumans030211 gastroenterology & hepatologybusinessBrazilHelicobacter
researchProduct

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

2021

Summary Non-invasive tests are increasingly being used to improve the diagnosis and prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis, focusing on the topics for which relevant evidence has been published in the last 5 years.

0301 basic medicinemedicine.medical_specialtyelastographyCirrhosisHepatologydecompensationbusiness.industrycirrhosisNon invasiveMEDLINENASHmedicine.diseaseClinical Practice03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicinemedicine030211 gastroenterology & hepatologyDecompensationIntensive care medicinebusinessserum markers of fibrosiscirrhosis decompensation elastography NASH serum markers of fibrosis
researchProduct

Association of Non-Invasive Markers of Liver Fibrosis with HCV Coinfection and Antiretroviral Therapy in Patients with HIV

2019

Abstract The aim of this study was to assess the main effects and interaction between viral hepatitis C (HCV) coinfection and antiretroviral therapy (ART) by using a nonparametric ANOVA on direct and indirect markers of liver fibrosis in HIV-infected patients. The sample included 178 HIV patients aged from 23 to 65 (36% females). The following parameters were determined in blood of patients: hyaluronic acid, pro-matrix metalloproteinase-1, alanine aminotransferase, aspartate aminotransferase, and platelet count. The FIB-4 index was also calculated. The nonparametric ANOVA revealed no significant interaction between HCV coinfection and ART. This provides evidence for an independent contribut…

0301 basic medicinemedicine.medical_specialtyfib-4Liver fibrosisScienceHuman immunodeficiency virus (HIV)medicine.disease_causeGastroenterologypro-mmp-103 medical and health sciences0302 clinical medicineInternal medicinehyaluronic acidmedicinePlateletliver fibrosisMultidisciplinaryaltNon invasiveQmedicine.disease030112 virologyAntiretroviral therapyCoinfection030211 gastroenterology & hepatologyAnalysis of variancenonparametric anovaViral hepatitisastProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

2017

0301 basic medicinemedicine.medical_specialtyhepacivirusHCV RASTreatment outcomeDrug ResistanceHCV genotypesDrug resistanceBiologyNS5A03 medical and health sciences0302 clinical medicineSecond linedrug resistance viral; humans; retreatment; treatment outcome; antiviral agents; hepacivirus; hepatitis c chronicInternal medicineDrug Resistance Viral; Humans; Retreatment; Treatment Outcome; Antiviral Agents; Hepacivirus; Hepatitis C ChronicDrug Resistance Viralantiviral agentsmedicineViralChronicNS5AhumansHepatologyhepatitis c chronicHepatitis CHepatitis C ChronicSettore MED/07 - Microbiologia e Microbiologia Clinicamedicine.diseaseHepatitis CVirologyHepatology HCV NS5A030104 developmental biologyHCVtreatment outcome030211 gastroenterology & hepatologyretreatmentdrug resistance viral
researchProduct

Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches

2021

Current treatment recommendations for non-alcoholic fatty liver disease (NAFLD) rely heavily on lifestyle interventions. The Mediterranean diet and physical activity, aiming at weight loss, have shown good results in achieving an improvement of this liver disease. However, concerns related to compliance and food accessibility limit the feasibility of this approach, and data on the long-term effects on liver-related outcomes are lacking. Insulin resistance is a central aspect in the pathophysiology of NAFLD; therefore, interventions aiming at the improvement of insulin sensitivity may be preferable. In this literature review, we provide a comprehensive summary of the available evidence on nu…

0301 basic medicinemedicine.medical_specialtyinsulinlifestyletime-restricted feedingsteatohepatitisDiseaseReviewmetabolic syndrome03 medical and health sciencesLiver disease0302 clinical medicineInsulin resistanceNon-alcoholic Fatty Liver DiseaseWeight lossIntermittent fastingmedicineTime‐restricted feedingHumansTX341-641Intensive care medicineLife StyleNutrition and DieteticsNon‐alcoholicbusiness.industryNutrition. Foods and food supplyintermittent fastinglow-carb dietFatty liverfibrosismedicine.diseaseDietGastrointestinal MicrobiomeLow‐carb diet030104 developmental biologynon-alcoholicFibrosis; Insulin; Intermittent fasting; Lifestyle; Liver disease; Low‐carb diet; Metabolic syndrome; Non‐alcoholic; Steatohepatitis; Time‐restricted feeding; Weight loss030211 gastroenterology & hepatologyInsulin ResistanceSteatohepatitismedicine.symptomMetabolic syndromeweight lossbusinessliver diseaseFood ScienceNutrients
researchProduct

2020

Understanding the importance of the gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat content associated with low abundance of Faecalibacterium prausnitzii in humans and, further, the administration of F. prausnitzii prevented NAFLD in mice. Here, we aimed at targeting F. prausnitzii by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on F. prausnitzii growth was assessed in vitro. Then, XOS was supplemented or not with high (HFD, 60% of energy from fat) or low (LFD) fat diet for 12 weeks in Wistar rats (n = 10/group). XOS increased F. prausnitzii growth, having onl…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentFaecalibacterium prausnitziiButyrateGut floradigestive system03 medical and health sciences0302 clinical medicineInternal medicinemedicinechemistry.chemical_classificationNutrition and DieteticsbiologyPrebioticFatty liverfood and beveragesnutritional and metabolic diseasesFatty acidmedicine.diseasebiology.organism_classification3. Good health030104 developmental biologyEndocrinologychemistry030211 gastroenterology & hepatologySteatosisSteatohepatitisFood ScienceNutrients
researchProduct